Micronoma

Micronoma Receives FDA Breakthrough Device Designation for OncobiotaLUNG, a New Liquid Biopsy Assay for Detecting Lung Cancer

SAN DIEGO–(BUSINESS WIRE)–Micronoma, the first biotechnology company to offer early cancer detection with a microbiome-driven liquid biopsy platform, today announced that its OncobiotaLUNG assay has received Breakthrough Device designation from the Food and Drug Administration (FDA). As a result, Micronoma can expect continued guidance and prioritized agency reviews of its upcoming clinical trial and concurrent […]

Micronoma Receives FDA Breakthrough Device Designation for OncobiotaLUNG, a New Liquid Biopsy Assay for Detecting Lung Cancer

The OncobiotaLUNG assay is the first blood microbiome-driven liquid biopsy with proven efficacy, including identifying cancer in its early stages Breakthrough device designation validates Micronoma’s goal to improve the current standard of care for patients exhibiting lung nodules by using microbial biomarkers to detect lung carcinomas as early as stage I disease SAN DIEGO, January […]

Scroll to top